An interventional study of Motor-cognitive exercise and Usual Care in Parkinson Disease (PD), sponsored by Annemette Lokkegaard. Recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by Annemette Lokkegaard · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Parkinson Disease with a site in Denmark — 12 open to participants now, 18 under way, 1 of them phase 3. Parkinson Disease · Denmark.
Among the 50 studies in Parkinson Disease with a site in Denmark, this one is the 23rd largest by planned enrollment of the 33 interventional ones that give a count, is one of 7 that started in 2025, is one of 23 with no phase, reaches primary completion later than 8 of the 17 other live ones, and was the 42nd registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →12 of the 50 studies in Parkinson Disease with a site in Denmark are open now. Recruiting first, the newest first:
University of Southern Denmark · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18+ · Healthy volunteers
Danish Research Centre for Magnetic Resonance · Sites in Denmark
Ages 18–80
Aarhus University Hospital · Sites in Denmark
Ages 50–80
Hoffmann-La Roche · Sites in Denmark, United States, Australia and 14 more countries
Ages 50–85
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 75 across the 33 interventional studies, 90 across the 17 observational. Of the 29 that completed or were terminated, 7 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 50 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Annemette Lokkegaard as lead sponsor.
Annemette Lokkegaard has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Parkinson Disease with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06324422University of AarhusExercise as Treatment of Fatigue in Parkinson´s Disease | 2026-12-01 |
| NCT05981261University of AarhusExperimental Pain in Parkinsons | 2027-01-01 |
| NCT07465107Annemette LokkegaardMotor and Cognitive Exercise in Parkinson's Disease. | 2027-02-14 |
| NCT06570824Danish Research Centre for Magnetic ResonancerTMS as an Intervention for Levodopa-induced Dyskinesia | 2027-05-01 |
| NCT07397377Danish Research Centre for Magnetic ResonanceprTMS as an Intervention for Bradykinesia in Parkinson's Disease | 2027-05-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies in Parkinson Disease with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to examine the effects of a specialized multi-modal intervention in patients with moderate to advanced Parkinson's disease (PD). The hypothesis is that a specialized motor- and cognitive exercise program in addition to usual care can improve gait and balance better than usual care alone.
48 patients with PD and a symptom duration of 4 or more years will be randomized 1:1 to either a control arm or to an intervention arm. The control arm will have usual management of their PD. The intervention arm will receive exercises aimed at both motor and cognitive impairments of PD over the course of 12 weeks.
The study has been designed in partnership with the Copenhagen Trial Unit (CTU), Copenhagen Univeristy Hospital, to ensure both internal and external validity. To increase reproducibility, detailed protocols for all training modalities will be shared along with the study results.
This study is a feasibility study with the intention of a following international multi-center study to corroborate the results. Both feasibility outcomes for the intervention itself and clinical outcomes for the participants will be published.
Intervention: The exercise program will consist of gait and balance training, lower body strength training and dual task training while treadmill walking. The program will include an individualized and progressive exercise program 3 times x 1 hour a week for 12 weeks with the following exercise modalities:
The program will be conducted under supervision by a physiotherapist or an exercise physiologist. Usual treatment is permitted during the trial, both pharmacological and non-pharmacological. The treatment is preferably stable during the intervention and follow-up, but necessary changes will be registered.
All participants will be examined at baseline, after 12 weeks and again 6 and 12 months after baseline.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The control arm will continue usual management (best medical treatment) of their PD and other potentiel comorbidities at the discretion of their regular physician and other health providers. Enrollment in this study will not influence any clinical decisions or potential changes in management.
Other: Usual Care
The intervention arm will receive 3 weekly 1-hour sessions of multi-modal training over the course of 12 weeks, totaling 36 sessions, in addition to usual management (best medical treatment). As with the control arm, any clinical decisions or potential changes in management will not be influenced be enrollment in this study.
Other: Motor-cognitive exercise
3 weekly 1-hour sessions of motor-cognitive exercise. Each 1-hour session will be multi-modal with 20 minutes of dynamic balance training, 20 minutes of dual-task exercises while treadmill walking and 20 minutes of lower body strength training with leg press. Detailed protocols for the exercises will be published along with results.
Best medical treatment: usual management of participants' PD and other potential comorbidities at the discretion of their regular physician and other health providers.
Feasibility: Intervention adherence
Adherence defined as the proportion of participation in exercise sessions out of 36. A proportion of more than 60% will be considered acceptable.
Time frame: From allocation to the end of 12 weeks of intervention (T2)
Exploratory composite clinical outcome: Significant fall, all-cause hospitalization and all-cause mortality
A composite outcome of either death, unplanned hospitalization or a significant fall. A significant fall will be defined as a fall leading to an unplanned hospital contact or contact with the general practitioner. This composite outcome is based on binary events that will be registered at each pre-specified follow-up time.
Time frame: From enrollment to 1-year follow-up (T4)
Feasibility: Missing data (primary clinical outcome)
Proportion of missing data on the exploratory primary clinical outcome "Significant fall, all-cause hospitalization and all-cause mortality". A proportion of less than 5% will be considered acceptable.
Time frame: From enrollment to 6-month follow-up (T3)
Feasibility: Missing data (secondary clinical outcomes)
Proportion of missing data on the exploratory secondary clinical outcomes. A proportion of less than 10% will be considered acceptable.
Time frame: At baseline (T1), end of intervention at 12 weeks (T2), follow-up at 6 months (T3) and follow-up at 1 year (T4).
Feasibility: Randomization rate
Screened compared to randomized. A rate of more than 70% randomized will be considered acceptable.
Time frame: From screening to baseline, up to 1 year.
Feasibility: Drop-out rate
Drop-out at any time after enrollment. A drop-out of about 20 % is expected.
Time frame: Through study completion, an average of 1 year
Feasibility: Treatment fidelity
Examination of attendance rate
Time frame: Through study completion, an average of 1 year
Exploratory secondary clinical outcomes
Hospital and institution free days
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Montreal Cognitive Assessment (MoCA)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Short Falls Efficacy Scale (Short-FES)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Parkinson's Disease Questionnaire (PDQ-39)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Mini Balance Evaluation Systems Test (Mini-BESTest)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
30-second Chair Stand Test (30s-CST)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year
Handgrip strength (HGS)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Timed Up and Go (TUG)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Physical activity, Diary
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Falls, diary
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Dual-task interference (DTi)
Time frame: Through study completion, an average of 1 year. The following time-points: Baseline, end of intervention at 12 weeks, follow-up at 6 months and follow-up at 1 year.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Feb 2027, 22 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 22 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.